ReviewParasitology research2009
Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use.
Review in Parasitology research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Schistosomiasis in Yemen: Focal Persistence, Possible Resurgence, and Challenges to Elimination.Research and reports in tropical medicine · 2026Review
- Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?RSC medicinal chemistry · 2020Review
- 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.Current neuropharmacology · 2020Review
- PZQ Therapy: How Close are we in the Development of Effective Alternative Anti-schistosomal Drugs?Infectious disorders drug targets · 2019Review
- Antischistosomal Properties of Hederacolchiside A1 Isolated fromMolecules (Basel, Switzerland) · 2018Article
- Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target.PLoS neglected tropical diseases · 2017Article
- Identifying Metabolites of Meclonazepam by High-Resolution Mass Spectrometry Using Human Liver Microsomes, Hepatocytes, a Mouse Model, and Authentic Urine Samples.The AAPS journal · 2017Article
- Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni.PLoS neglected tropical diseases · 2016Article
- Viability of developmental stages of Schistosoma mansoni quantified with xCELLigence worm real-time motility assay (xWORM).International journal for parasitology. Drugs and drug resistance · 2015Article
- Biomphalaria alexandrina in Egypt: past, present and future.Journal of biosciences · 2013Review
- Combination therapy using Pentostam and Praziquantel improves lesion healing and parasite resolution in BALB/c mice co-infected with Leishmania major and Schistosoma mansoni.Parasites & vectors · 2013Article
- Genetic variation between Biomphalaria alexandrina snails susceptible and resistant to Schistosoma mansoni infection.BioMed research international · 2013Article
- Immunohistopathological changes in murine Schistosomiasis mansoni under the influence of N-acetyl-L-cysteine.Parasitology research · 2012Article
- Effect of the in vivo activity of dihydroartemisinin against Schistosoma mansoni infection in mice.Parasitology research · 2012Article
- Effects of artemether, artesunate and dihydroartemisinin administered orally at multiple doses or combination in treatment of mice infected with Schistosoma japonicum.Parasitology research · 2011Article
- IL-10 blocks the development of resistance to re-infection with Schistosoma mansoni.PLoS pathogens · 2011Article
- A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility.PLoS neglected tropical diseases · 2010Article
- RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening.PLoS neglected tropical diseases · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schistosomiasis is a chronic parasitic disease affecting about 207 million people in the world. It still represents a major health problem in many tropical and sub-tropical countries as well as for travelers from developed countries. Control of the disease depends mainly on chemotherapy, with praziquantel becoming the exclusive drug. Extensive use of praziquantel with concerns about the possibility of drug resistance development, unavailability of an applicable vaccine, and the absence of a reasonable alternative to praziquantel all represent a real challenge. One of the suggested solutions is to exploit the advantages of compounds that proved efficacious at the experimental level with a good safety profile. These may undergo further investigations for the sake of developing their antischistosomal properties or to incorporate them in combination therapies. Chemotherapy literature is redundant with a huge number of compounds screened for their schistosomicidal properties. However, only a few of these may act as drug leads that could be promising in the development of a therapeutic reserve for schistosomiasis. The present paper reviews previous studies carried out on some of these compounds.
Indexed as
Identifiers
19588166What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.